Analyst Price Targets — ENTA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 23, 2026 10:52 am | Brandon Folkes | H.C. Wainwright | $20.00 | $13.37 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA) |
| October 1, 2025 2:21 pm | Akash Tewari | Jefferies | $20.00 | $10.88 | TheFly | Enanta upgraded to Buy from Hold at Jefferies |
| June 3, 2025 9:37 am | Roy Buchanan | JMP Securities | $24.00 | $7.19 | TheFly | Enanta price target raised to $24 from $23 at Citizens JMP |
| December 9, 2022 6:10 am | — | H.C. Wainwright | $56.00 | $41.96 | Benzinga | HC Wainwright & Co. Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces Price Target of $56 |
| November 22, 2022 7:39 am | — | RBC Capital | $54.00 | $46.40 | Benzinga | RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Lowers Price Target to $54 |
| July 29, 2022 10:32 am | Yasmeen Rahimi | Piper Sandler | $87.00 | $51.28 | TheFly | Enanta's 'strong' EDP-235 data supports 'impressive' profile, says Piper Sandler |
Latest News for ENTA
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy, for the treatment of acute HCV infection without…
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced it is advancing zelicapavir into a registrational Phase 2b/3 clinical trial in adults at high risk of severe outcomes from RSV infection after a successful End-of-Phase 2 meeting with the U.S.…
[url="]Enanta Pharmaceuticals, Inc.[/url] (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ENTA.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.